High levels of Epstein-Barr virus in the oropharynx: A predictor of disease progression in human immunodeficiency virus infection
✍ Scribed by Dr. Francisco Diaz-Mitoma; Alejandra Ruiz; Gordon Flowerdew; Stanley Houston; Barbara Romanowski; T. Kovithavongs; Jutta Preiksaitis; D. Lorne Tyrrell
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 802 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The role of Epstein‐Barr virus (EBV) on the progression of human immunodeficiency virus (HIV) infection is not well defined. The objective of this prospective study was to determine the prevalence of EBV excretion and the rol that EBV might have on HIV disease progression. Fifty‐two homosexual males were studied, all of whom had positive EBV serology. Twenty‐four of the 27 HIV‐seropositive and 14 of the 25 HIV‐seronegative subjects had detectable levels of EBV DNA in oropharyngeal cells. In addition to a greater prevalence of detectable EBV, the level of excretion was higher among HIV‐seropositives than among HIV‐seronegatives, and higher among group III than among group II HIV‐seropositive men. These results are consistent with earlier studies showing a relationship between immunosuppression and EBV reactivation. The EBV excretion levels in a control group of 52 age‐matched heterosexual males were substantially lower than those found in the homosexual group.
In a proportional hazards regression analysis EBV excretion was found to be the best single predictor of progression of HIV infection (P<0.001). HIV p24 core antigenemia (P=0.048) and low EBNA (P=0.024) were significant predictors independent of EBV excretion. Whether EV directly accelerates the time to progression or is merely a marker of underlying subclinical immunosuppression remains an open question.
📜 SIMILAR VOLUMES
## Abstract Epstein‐Barr virus (EBV) reactivation is more likely to occur in immunocompromised patients with subsequent higher susceptibility to EBV‐associated lymphoproliferations. In contrast to transplant recipients, limited data are available concerning the EBV load in HIV‐infected patients, wi
## Abstract Interaction between herpesviruses and human immunodeficiency virus (HIV)I is postulated in the progression of HIV disease. In order to evaluate the specific antibody responses directed to Epstein‐Barr virus (EBV) and cytomegalovirus (CMV) and to provide serological evidence suggesting r
We studied the prevalence of four serum factors in individuals at different stages of human immunodeficiency virus-1 (HIV-1) infection. Soluble interleukin-2 receptors (slL-2R) were elevated in all antibody-positive groups compared with high-risk, antibodynegative controls. Paraproteins, usually of
Hodgkin's disease (HD) is associated with the Epstein-Barr virus (EBV) in approximately half of cases. This is a report of a case of nodular sclerosing HD of the B-cell type that was associated with EBV in the initial manifestation, but was found to be EBV-negative in the relapse of the tumour. Both
Sixty cases of B-cell nodal nonHodgkin's malignant lymphoma (B-ML), and 46 cases of T-cell nodal lymphoma (T-ML) were surveyed for Epstein-Barr virus (EBV) genomes, RNA, and associated proteins. We used a Southern blot analysis, polymerase chain reaction (PCR), and EBV-encoded small RNA-1 (EBER-1) i